Rabbit antithymocyte globulin as first-line therapy for severe aplastic anemia

Area of Science:

• Hematology
• Immunosuppressive Therapy
• Aplastic Anemia Research

Background:

• Rabbit antithymocyte globulin (rATG) is effective for refractory aplastic anemia (AA).
• Previous trials on rATG as first-line therapy for AA yielded variable results.
• Cyclosporin A (CsA) is a standard treatment for AA.

Purpose of the Study:

• To evaluate the efficacy of rATG plus CsA as first-line therapy for severe AA (SAA) and very severe AA (VSAA).
• To assess hematologic response and survival rates in SAA/VSAA patients.
• To identify predictive factors for treatment outcomes.

Main Methods:

• Retrospective analysis of 292 newly diagnosed SAA/VSAA patients treated with rATG and CsA.
• Assessment of response rates at 3, 6, 9, and 12 months post-therapy.
• Multivariate analysis to identify prognostic factors for survival.

Main Results:

• Overall response rates reached 68.5% at 12 months.
• Five-year overall survival was 83.2%, and 5-year event-free survival was 67.2%.
• Initial response to granulocyte colony-stimulating factor (G-CSF) predicted 12-month response; neutrophil count and early response to rATG predicted overall survival.

Conclusions:

• First-line treatment with rATG and CsA is safe and effective for SAA/VSAA.
• The combination therapy leads to favorable long-term hematologic response and survival.
• Neutrophil count and early response to rATG are key prognostic indicators for survival.